Garry Neil, Avalo Therapeutics CEO
Avalo Therapeutics to lay off 33% of staff amidst market struggles and penny stock status
Avalo Therapeutics is continuing to hit bumps in its journey as it is executing a workforce reduction to focus more on its pipeline.
The Rockville …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
